Knight Therapeutics Inc (TSE:GUD) had its price objective decreased by Scotiabank from C$10.00 to C$9.50 in a research note published on Friday morning, reports. Scotiabank currently has an outperform rating on the stock.

Separately, CIBC upped their target price on shares of Knight Therapeutics from C$9.50 to C$9.80 in a research note on Friday, November 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of C$9.83.

Knight Therapeutics (TSE:GUD) opened at 9.78 on Friday. Knight Therapeutics has a 1-year low of $5.89 and a 1-year high of $9.86. The firm has a market cap of $1.30 billion and a price-to-earnings ratio of 68.87. The company’s 50 day moving average is $9.20 and its 200-day moving average is $8.65.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Stock Target Prices

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.